The landscape of pediatric RTK-driven gliomas
Oncogenic fusions involving receptor tyrosine kinases (RTK) provide an excellent opportunity for therapeutic targeting but the clinical and molecular landscape of pediatric RTK-driven gliomas remains largely uncharted. To define clinically-relevant tumor subgroups and assess their prognostic significance, we will evaluate the correlation between molecular and clinical characteristics. This project will provide mechanistic insights into RTK-fused gliomas and enable precision medicine approaches to treat these tumors.
Ana Guerreiro Stücklin
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su